Data points to no age-related cutoff for mammogram screenings | RSNA 2016 Roundup

There is no clear cut-off age to stop breast cancer screening, according to new data from the largest-ever study on mammogram screening outcomes. Data from the study was presented this week at the Radiological Society of North America’s annual meeting. Age-based cutoffs for screenings have been a source of controversy for many years in the healthcare field. Results from the massive study, however, support guidelines that support making breast cancer screening decisions based on individual patients and health status over a specific age, according to study researchers. Data in the study came from over 5.6 million mammogram screenings performed over 7 years between January 2008 and December 2014 and across 150 facilities in 31 U.S. states. Patient demographic data, mammography and biopsy results were considered in the analysis, with over 2.5 million women over 40 in the study. A total of 4 standard performance metrics were used to evaluate the data at each age group, including cancer detection rate, recall rate, positive predictive value for biopsies and biopsies performed. The mean rate of cancer detection was clocked at 3.74 per 1,000 patients, with a recall rate of 10%, positive predictive value of recommended biopsies at 20% and for biopsies performed at 29%. In considering age between 40 and 80 years, metrics showed a gradualte upward trend in terms of cancer detection rate and biopsy prediction rate, but a downward trend in recall rate. “All prior randomized, c...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Imaging Oncology Radiological Society of North America Source Type: news

Related Links:

Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases, Published online: 22 February 2019; doi:10.1038/s41388-019-0756-zEstradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases
Source: Oncogene - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsThe evidence for equine ‐assisted interventions for adults and children across a range of conditions and presentations is equivocal. The current evidence base is marred by multiple methodological weaknesses and thus, therapeutic interventions that include a horse cannot be asserted as best practice at this time. Rigorous research is indicated to determine the utility of equine‐assisted interventions.
Source: Australian Journal of Psychology - Category: Psychiatry & Psychology Authors: Tags: SPECIAL ISSUE Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Abstract Over the last decade there has been growing evidence that Brain Expressed X-Linked 2 (BEX2) has a significant role in the process of carcinogenesis. Collectively, available studies suggest a pro-oncogenic function for this gene in multiple malignancies, including breast, colorectal and hepatocellular cancers in addition to brain tumors. The identification of BEX2 in breast cancer resulted from gene expression microarray studies. Subsequent studies showed that BEX2 promotes breast cancer cell growth and survival by modulating the mitochondrial apoptotic pathway and G1 cell cycle. In this process, BEX2 has ...
Source: Experimental Cell Research - Category: Cytology Authors: Tags: Exp Cell Res Source Type: research
By analyzing tumor characteristics such as structure, shape, and size, an artificial...Read more on AuntMinnie.comRelated Reading: AI may predict lymph node metastasis in gastric cancer AI can predict breast cancer molecular subtypes on MRI Russian AI detects lung cancer on CT in 20 seconds AI can differentiate glioblastoma, brain metastasis AI uses features outside nodules to predict malignancy
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Opinion statementIn the past, the standard of care for treatment of BM was whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), and surgery. There has been a greater role for medical therapies in the last two decades due to the discovery of driver mutations and corresponding targeted therapies. These innovations have dramatically altered the approach to treating these patients. Some of the important mutations include epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations in small cell lung cancer, human epidermal growth factor receptor (HER2) mutation in breast cancer, and ...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
Publication date: February 2019Source: Brain, Behavior, and Immunity, Volume 76, SupplementAuthor(s): C. Taub, H. Fisher, E. Nahin, B. Blomberg, M. Lippman, B. Hudson, A. Diaz, S. Lechner, T. Kwak, G. Hwang, C. Carver, M. AntoniInflammation and social adversity have been linked to poorer long-term outcomes in breast cancer (BCa) patients, whereas greater social and family well-being (sfwb) relates to less inflammation and longer disease-free interval in BCa. S100A8A9 is a RAGE-related ligand that can up-regulate inflammatory and pro-metastatic processes and has been associated with increased risk of BCa metastasis. Here we...
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
Conclusion.In this cohort of patients with GI cancer with brain metastases, HER2+ status was more common intracranially compared with prior sites of disease. These findings suggest that testing HER2 in patients with GI cancer with brain metastases may lead to additional therapeutic options, regardless of HER2 status in previously examined tissue.Implications for Practice.HER2 amplification is a well‐known driver of oncogenesis in breast cancer, with associated increased risk of brain metastases and response to HER2‐directed therapy. In nongastric gastrointestinal (GI) cancers, HER2 amplification is not common and conse...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Precision Medicine, Cancer Diagnostics and Molecular Pathology, Gastrointestinal Cancer Source Type: research
The combination of artificial intelligence (AI) and radiomics features on CT...Read more on AuntMinnie.comRelated Reading: AI can predict breast cancer molecular subtypes on MRI Russian AI detects lung cancer on CT in 20 seconds AI can differentiate glioblastoma, brain metastasis AI uses features outside nodules to predict malignancy Surgery plus RT works best for metastatic gastric cancer
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Working with radiomics data on multiparametric MRI (mpMRI) scans, an artificial...Read more on AuntMinnie.comRelated Reading: Advanced imaging offers insight into targeted therapies AI can predict breast cancer molecular subtypes on MRI AI can differentiate glioblastoma, brain metastasis CT radiomics improves management of bile duct cancer Faster MRI protocol avoids unneeded prostate biopsies
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
More News: Angiography | Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Databases & Libraries | Heart | Lung Transplant | Mammography | Neurology | Partnerships | Radiography | Study | Ultrasound | Women